Dr Swee Tan wins Medicines New Zealand Award for research The
Transcription
Dr Swee Tan wins Medicines New Zealand Award for research The
Newsletter / ISSUE #3, December 2014 Please visit the following link to donate www.gmri.org.nz/donate The Wellys honour Dr Swee Tan It’s not just Gillies McIndoe Research Institute supporters who acknowledge the wonderful work of our founder and executive director, Dr Swee Tan - he’s now been publicly recognised by the prestigious annual Wellingtonian of the Year Awards. Dr Tan was recently named as the winner of the 2014 Wellingtonian of the Year Awards’ Science and Technology category and was described as being “greatly respected by the international medical and science community and his patients and their families for his pioneering work in vascular birthmarks and cancer”. The Wellys, as the awards are affectionately known, recognise members of the Wellington community who have made outstanding contributions in their field. This year’s supreme award was won by basketballer Steven Adams. “Those of us who work closely with Swee know this award is richly deserved,” said the GMRI chair, Paul Baines. “It’s a privilege to be part of the GMRI community which he founded.” Dr Swee Tan (left) receiving the Science and Technology Award from Ray Wallace (right), Mayor of Hutt City. Photo credit: John Nicholson, The Dominion Post, Fairfax NZ. Swee, himself, says the real credit lies with his team and their collaborators. “It is an acknowledgement that also belongs to the team at the GMRI and my colleagues in the medical and science communities who, over a long period of time, have been part of the quest to find a better way to relieve human suffering.” The Wellys honour comes hot on the heels of the Value of Medicines Award (see story in this issue) which was presented to Swee recently by Medicines New Zealand. Dr Swee Tan wins Medicines New Zealand Award for research Dr Swee Tan has scooped the Medicines New Zealand 2014 Value of Medicines Award for his outstanding work treating newborn babies suffering from disfiguring and life-threatening strawberry birthmarks. From left, Hon Heather Roy, Chair of Medicines New Zealand, Dr Swee Tan and Hon Peter Dunne. Medicines New Zealand’s $20,000 award aims to stimulate research and advance understanding, effectiveness or safety of the use of medicines or vaccines. Work nominated for the award must be of direct relevance to the current or future provision of healthcare in New Zealand. – Continued over page. Hon Heather Roy, Chair of Medicines New Zealand, said “Dr Tan’s work is an exemplary piece of medical research and is precisely the type of nomination we look for in the Value of Medicines Award. “New Zealand is home to a wealth of medical knowledge and expertise which deserves to be celebrated. Through this award we are shining a light on the research heroes who are advancing medicines and vaccines that can improve the health of New Zealanders and potentially save lives. “Dr Tan’s outstanding and tireless research into the treatment of problematic strawberry birthmarks in babies met all the criteria for the award and it is with the greatest pleasure that we are able to celebrate with him in the success of his work.” Dr Tan’s team at the GMRI found that strawberry birthmarks are caused by stem cells regulated by a hormone system. Their discoveries underscore the new treatment that leads to dramatic shrinkage of strawberry birthmarks within months, negating the need for the traditional treatment using high-dose steroids, and lengthy and complicated surgery over several years. The GMRI’s ground-breaking research into, and discoveries of, strawberry birthmarks has potentially enormous implications for the treatment of other tumours, including cancer. “It is an honour to be recognised with this prestigious award,” Dr Tan said. “However, the real tributes should go to all the brave children and their families whose lives have been so affected by this condition. Credit also goes to the team at the GMRI and all my colleagues in the medical and science communities who have been involved in the quest to find a better way to manage this tumour.” He said the $20,000 funding associated with the award will be used for furthering research into cancer at the GMRI, building on current work. Hon Peter Dunne presented the Value of Medicines Award to Dr Tan at a function at Parliament in November. Cherise Tan. percent of patients treated with the 'standard’ dosage. “Hopefully this will improve patient outcomes because it will lead to lower doses of the drug being used around the world,” Cherise said. “At the very least, I hope it generates more research on this issue.” New research benefits babies Parents of babies with strawberry birthmarks could have Cherise Tan to thank for making their children’s treatment safer. A fourth year medical student at the University of Otago, Wellington, Cherise (22), has recently published her research in the prestigious Journal of Paediatrics and Child Health. Cherise’s article presents the results of using a low-dose propranolol regime for the treatment of strawberry birthmarks. Her research shows that halving the dosage of the drug is just as efficacious, but reduces the incidence of side-effects. Of the 44 patients in the study, just three had minor side-effects. One developed constipation and two had sleep disturbances. Cherise says this is a complication rate of just 6.8 percent of patients, compared to a rate of up to 61.2 Propranolol, a drug normally used in the treatment of certain heart conditions and high blood pressure, was found to shrink strawberry birthmarks in 2008. However, various studies have shown relatively high complication rates at the ‘standard’ dosage of 2-3mg/kg/day, used worldwide currently. New Zealand babies were first treated with a lower dose of propranolol by Dr Phillip Leadbitter, a paediatrician, and Dr Swee Tan, founder and director of the Centre for the Study and Treatment of Vascular Birthmarks, based at Hutt Hospital. Cherise’s results are based on a study of patients treated between 2009 and 2013. She conducted the research and wrote the research paper over the summer of 20122013, as one of five summer – Continued over page. students at the Gillies McIndoe Research Institute. She was supervised by Dr Tan, also the executive director of the GMRI, and Dr Leadbitter of Hutt Hospital. “People my age don’t usually get the chance to do research like this so it was a wonderful opportunity,” Cherise says. “The paper was actually published on my birthday in September so that was a very nice present.” Cherise says one of the best parts about the summer studentship was meeting some of the children and their families involved in the study One of the cases in Cherise’s paper - a three month old girl with a large, rapidly growing strawberry birthmark on her cheek and ear before (left) and at 13 months (right) following low-dose propranolol treatment. when she sat in on the patient consultations at the clinics run by Drs Tan and Leadbitter at Hutt Hospital. Cherise undertook the studentship with the support of a scholarship provided by Sir Roderick and Lady Gillian Deane. Is there something in the water at the GMRI? Frederica Steiner. Frederica’s research found both treatments are beneficial, providing positive quality of life outcomes and patient satisfaction levels. They both reduce pain, swelling and skin discolouration, while generating a limited number of complications. “My research indicates that the preferred treatment option depends on the specifics of the case, and to some degree on patient preference,” she says. To complete her research, Frederica surveyed 50 patients who underwent surgery, and 54 patients who received alcohol injections between 1996 and 2011. There must be something in the water at the GMRI – Frederica Steiner is the second summer student to have the research she conducted at the Institute recently published in prestigious medical journals. She designed the survey questionnaire herself and contacted the patients over the summer of 2011-2012 to have them complete it. In some cases she interviewed the patients by phone. – Continued over page. Frederica (23) is in her final year studying medicine at the University of Otago, Wellington. She has had two papers published, one in the Journal of Plastic, Reconstructive and Aesthetic Surgery and the other in the ANZ Journal of Surgery. Her papers assess the effects of treating venous malformation (VM), a type of vascular birthmark, with alcohol injections or surgery. Frederica describes VM in layperson’s language as a condition in which the affected veins have thinner and weaker walls that ‘blow out’ and cause blood to pool rather than flow efficiently. The condition, affecting one percent of the population, causes disfigurement, pain and loss of function. One treatment option is to inject pure alcohol directly into the VM, causing the affected veins to scar-up and close. Another option is surgery, which generally aims to remove the entire VM. One of the cases in Frederica’s paper - a six year old girl with a venous malformation on her face before (left) and after (right) alcohol injections. Frederica was offered the summer studentship at the GMRI after hearing Dr Swee Tan speaking at a university presentation. She contacted Dr Tan and asked if she could do research for him, and was subsequently given the VM research assignment. How does she feel about being published? “A bit of relief actually,” she says. “I am really happy to be published. It took a lot of effort and I’m proud of what I have achieved. “Without Dr Tan’s help this wouldn’t have happened and I’m very grateful to have been given the opportunity.” Aspiring to be a paediatrician and graduating this year, Frederica was supervised during her summer studentship by Dr Tan and Dr Trevor FitzJohn of the Centre for the Study and Treatment of Vascular Birthmarks, based at Hutt Hospital. New health partnership to progress cancer cure The GMRI has established a new health partnership with the Wairarapa, Hutt Valley, and Capital & Coast DHBs in a move that will translate laboratory research into radically improved treatment of diseases, including cancer. Capital & Coast and Hutt Valley DHBs’ chair, Dr Virginia Hope. The DHBs have signed a formal memorandum of understanding with the GMRI to promote close interchange, collaboration and sharing of ideas between leading DHB clinicians and the GMRI’s scientists. “With persistence and the right environment, more effective treatment of many conditions can be found in the future,” Dr Swee Tan says. “The agreement signifies that this is a view shared by the GMRI and the DHBs. Our organisations already have much in common. With a closer working relationship we will be able to enhance research and improve educational, business, health and social outcomes.” Wairarapa and Hutt Valley DHB chief executive, Graham Dyer, is pleased to formalise the relationship the GMRI has had with the DHBs for many years. “During much of this time, the team was based at Hutt Hospital and various clinical groups have collaborated with the GMRI on many research projects.” Interim chief executive, Debbie Chin, says Capital & Coast DHB is thrilled to be able to accommodate the Institute in a new purpose-built laboratory next to Wellington Hospital. “Our close working relationship with our neighbours in the Hutt Valley and Wairarapa already enables us to provide more convenient care for our patients and our aim is to extend these benefits further.” Capital & Coast and Hutt Valley DHBs’ chair, Dr Virginia Hope, says many highly-regarded international experts and organisations understand the immense potential of the discoveries made by Swee’s team, and their implications for the treatment of cancer. “This MOU enshrines the collaboration and cooperation that has been a feature of Swee’s and the GMRI’s work,” she said. Be part of our journey Dr Swee Tan and his team at the GMRI have achieved remarkable success in advancing knowledge relating to strawberry birthmarks and other tumours. This work has the potential to lead to fundamental advances in the understanding and treatment of cancer. Our scientists are committed to building on the important, internationally-recognised progress they have made to date. It is an exciting journey, made possible, in large part, due to the support and involvement of many people and organisations. Please continue to support the GMRI, which depends on the generosity of donors. Please contribute to our Paua Butterfly Campaign - the Donate Now button (www.gmri.org.nz) will take you to a range of options to make a donation. Please visit the following link to donate www.gmri.org.nz/donate To receive this newsletter via email in the future, please email your name(s) to [email protected] Gillies McIndoe Research Institute | www.gmri.org.nz PO Box 7184, Newtown, Wellington South 6242, New Zealand | Phone: +64 282 0366 | Email: [email protected]